Michael J Haller, M.D.
Professor And Chief
About Michael J Haller
Hello! My name is Dr. Haller but my patients call me Dr. Mike. I work as a Professor and Chief of Pediatric Endocrinology at the University of Florida. As a Gainesville native, and the child of two teachers, I was exposed from an early age to the many incredible educational opportunities afforded by our diverse and highly educated city. My early interests in biology and chemistry combined with my desire to help people and work with children led me pretty directly towards pursuing a career in pediatrics. My interest in pediatric endocrinology was shaped by my grandfather’s experience living with diabetes, experiences volunteering at the Florida Diabetes Camps, and exceptional mentoring from Drs. Desmond Schatz, Janet Silverstein and Mark Atkinson.
I have been involved in type 1 diabetes research since the early 1990s and have published over 200 manuscripts and more than 20 reviews/book chapters on type 1 diabetes pathogenesis, prevention, and interdiction. I am the principal investigator or co-investigator on numerous JDRF, NIH, and Helmsley trust funded studies. My goal is to work every day to improve the lives of children and families affected by type 1 diabetes. I am hopeful that during my career we will develop therapies that can meaningfully prevent and reverse type 1 diabetes.
In my free time, I enjoy spending time with my wife, Dr. Allison Haller (an Anesthesiologist and also a Gator Med School Grad), our 2 children, and our dogs. I also love to spend time in nature, watch live music, attend Gator sporting events, and fly planes.
Accomplishments
UF Research Professorship
2017-2020
·
University of Florida
Silverstein Family Eminent Scholar Chair
2016
·
University of Florida
Young Investigator Award
2010
·
ISPAD
Cure Award
2009
·
ADA
Mary Tyler Moore Excellence in Clinical Research Award
2008
·
JDRF
Society for Pediatric Research
2008
·
Society for Pediatric Research
JDRF Early Career Research Award
2007
·
JDRF
Kokomoor Award
2005
·
University of Florida
Douglass J Barrett Fellowship
2004
·
University of Florida
Teaching Profile
Courses Taught
2018
MDC7400 Pediatric Clerkship
2018
GMS7979 Advanced Research
2018
GMS7980 Research for Doctoral Dissertation
2017-2018
NGR7980 Research for Doctoral Dissertation
2018
MDT7400 Elect Top/Pediatrics
2017
EGN4912 Engineering Directed Independent Research
2023
GMS6383 Current Topics in Immunotherapy
2024
BMS6091 Hlth Outcomes Plcy 1
Board Certifications
-
Pediatric EndocrinologyAmerican Board of Pediatrics
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Pediatrics
Subspecialties
- Pediatric Endocrinology
Areas of Interest
- Pediatric pituitary and skull base services
- Type 1 diabetes
Research Profile
Dr. Haller’s research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.
Areas of Interest
- Prevention and intervention trials in Type 1 diabetes
- Type 1 Diabetes Treatment
Open Researcher and Contributor ID (ORCID)
0000-0002-2803-1824
Publications
2024
Confronting Health Misinformation Surrounding COVID-19 Vaccines in the State of Florida
Journal of General Internal Medicine.
39(8):1488-1491
[DOI] 10.1007/s11606-024-08726-6.
[PMID] 38499724.
2024
Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes
Diabetologia.
67(9):1731-1759
[DOI] 10.1007/s00125-024-06205-5.
[PMID] 38910151.
2024
Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes
Diabetes Care.
[DOI] 10.2337/dci24-0042.
[PMID] 38912694.
2024
Correction to: Consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes
Diabetologia.
67(9):2012-2014
[DOI] 10.1007/s00125-024-06266-6.
[PMID] 39230637.
2024
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
Diabetes care.
47(6):1048-1055
[DOI] 10.2337/dc24-0171.
[PMID] 38621411.
2024
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes
Diabetes Care.
47(2):285-289
[DOI] 10.2337/dc23-1750.
[PMID] 38117469.
2024
Multisite Quality Improvement Program Within the Project ECHO Diabetes Remote Network
The Joint Commission Journal on Quality and Patient Safety.
50(1):66-74
[DOI] 10.1016/j.jcjq.2023.08.001.
2024
Not all healthcare inequities in diabetes are equal: a comparison of two medically underserved cohorts
BMJ Open Diabetes Research & Care.
12(4)
[DOI] 10.1136/bmjdrc-2024-004229.
[PMID] 39242122.
2024
One-Year Thermostability of Commercial Glargine and Human Insulin
Diabetes Care.
[DOI] 10.2337/dc24-1749.
2024
Project Extension for Community Healthcare Outcomes Intervention Evaluations: A Scoping Review of Research Methods.
The Journal of continuing education in the health professions.
[DOI] 10.1097/CEH.0000000000000572.
[PMID] 39162718.
2024
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool
CPT: Pharmacometrics & Systems Pharmacology.
13(8):1309-1316
[DOI] 10.1002/psp4.13193.
[PMID] 38961520.
2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
Diabetes Care.
46(5):1005-1013
[DOI] 10.2337/dc22-2200.
[PMID] 36920087.
2023
Blue Circle Health: A Novel Patient-Centered Model of Health Care Delivery for Low-Income Patients With Type 1 Diabetes.
Journal of diabetes science and technology.
17(4):925-934
[DOI] 10.1177/19322968221149008.
[PMID] 36710449.
2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study
Diabetes Care.
46(3):526-534
[DOI] 10.2337/dc22-1297.
[PMID] 36730530.
2023
Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies.
CPT: pharmacometrics & systems pharmacology.
12(7):1016-1028
[DOI] 10.1002/psp4.12973.
[PMID] 37186151.
2023
Human immune phenotyping reveals accelerated aging in type 1 diabetes
JCI Insight.
8(17)
[DOI] 10.1172/jci.insight.170767.
[PMID] 37498686.
2023
Hydroxychloroquine in Stage 1 Type 1 Diabetes
Diabetes Care.
46(11):2035-2043
[DOI] 10.2337/dc23-1096.
[PMID] 37708415.
2023
Modeling the progression of Type 2 diabetes with underlying obesity
PLOS Computational Biology.
19(2)
[DOI] 10.1371/journal.pcbi.1010914.
[PMID] 36848379.
2023
Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes
JCI Insight.
8(16)
[DOI] 10.1172/jci.insight.161812.
[PMID] 37432736.
2023
Sociodemographic factors associated with major depressive episodes and suicidal ideation among emerging adults with diabetes in the U.S.
Frontiers in endocrinology.
14
[DOI] 10.3389/fendo.2023.1276336.
[PMID] 38144571.
2023
The Promising Success of Project Extension for Community Healthcare Outcomes (ECHO) Diabetes: Case Series
JMIR Diabetes.
8
[DOI] 10.2196/46050.
[PMID] 37535407.
2023
The role of health system penetration rate in estimating the prevalence of type 1 diabetes in children and adolescents using electronic health records.
Journal of the American Medical Informatics Association : JAMIA.
31(1):165-173
[DOI] 10.1093/jamia/ocad194.
[PMID] 37812771.
2023
Time for changes in type 1 diabetes intervention trial designs.
The lancet. Diabetes & endocrinology.
11(11):789-791
[DOI] 10.1016/S2213-8587(23)00262-0.
[PMID] 37802093.
2023
Time-Action Profile of Technosphere Insulin in Children with Type 1 Diabetes.
Diabetes therapy : research, treatment and education of diabetes and related disorders.
14(3):611-617
[DOI] 10.1007/s13300-023-01368-7.
[PMID] 36652106.
2022
Accuracy of Three Commercial Home-Use Hemoglobin A1c Tests
Diabetes Technology & Therapeutics.
24(11):789-796
[DOI] 10.1089/dia.2022.0187.
2022
Challenges and Opportunities in Using Telehealth for Diabetes Care
Diabetes Spectrum.
35(1):33-42
[DOI] 10.2337/dsi21-0018.
[PMID] 35308158.
2022
Commercially Available Insulin Products Demonstrate Consistency With Product Labeling Throughout All Seasons in the U.S.
Diabetes Care.
45(11):e166-e168
[DOI] 10.2337/dc22-0972.
2022
Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 Diabetes
Diabetes Technology & Therapeutics.
24(4):258-267
[DOI] 10.1089/dia.2021.0329.
2022
HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children
Pediatric Diabetes.
23(8):1586-1593
[DOI] 10.1111/pedi.13413.
[PMID] 36082496.
2022
Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study.
Diabetes care.
45(3):624-633
[DOI] 10.2337/dc21-0422.
[PMID] 35043162.
2022
ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents
Pediatric Diabetes.
23(8):1175-1187
[DOI] 10.1111/pedi.13410.
2022
The association of physical activity to oral glucose tolerance test outcomes in multiple autoantibody positive children: The TEDDY Study
Pediatric Diabetes.
23(7):1017-1026
[DOI] 10.1111/pedi.13382.
[PMID] 35702057.
2022
The progression of secondary diabetes: A review of modeling studies.
Frontiers in endocrinology.
13
[DOI] 10.3389/fendo.2022.1070979.
[PMID] 36619543.
2022
Type 1 diabetes knowledge assessment: The KAT ‐1 validation study
Pediatric Diabetes.
23(8):1687-1694
[DOI] 10.1111/pedi.13414.
2022
Using Peer Power to Reduce Health Disparities: Implementation of a Diabetes Support Coach Program in Federally Qualified Health Centers
Diabetes Spectrum.
35(3):295-303
[DOI] 10.2337/dsi22-0004.
[PMID] 36082018.
2021
A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.
Diabetes care.
44(2):464-472
[DOI] 10.2337/dc20-1060.
[PMID] 33334807.
2021
A unified mathematical model of thyroid hormone regulation and implication for personalized treatment of thyroid disorders.
Journal of theoretical biology.
528
[DOI] 10.1016/j.jtbi.2021.110853.
[PMID] 34358537.
2021
Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study.
Pediatric diabetes.
22(2):360-368
[DOI] 10.1111/pedi.13149.
[PMID] 33179853.
2021
Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes
Diabetes Care.
44(7):1480-1490
[DOI] 10.2337/dc20-2753.
[PMID] 34001535.
2021
Delayed diagnosis of diabetic ketoacidosis and associated mortality during the COVID-19 pandemic.
Journal of diabetes.
13(10):837-839
[DOI] 10.1111/1753-0407.13208.
[PMID] 34196115.
2021
Democratizing type 1 diabetes specialty care in the primary care setting to reduce health disparities: project extension for community healthcare outcomes (ECHO) T1D
BMJ Open Diabetes Research & Care.
9(1)
[DOI] 10.1136/bmjdrc-2021-002262.
[PMID] 34244218.
2021
Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.
Diabetes.
70(4):944-954
[DOI] 10.2337/db20-0995.
[PMID] 33441381.
2021
Feasibility of the Web-Based Intervention Designed to Educate and Improve Adherence Through Learning to Use Continuous Glucose Monitor (IDEAL CGM) Training and Follow-Up Support Intervention: Randomized Controlled Pilot Study
JMIR Diabetes.
6(1)
[DOI] 10.2196/15410.
[PMID] 33560234.
2021
Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis.
Diabetes.
70(4):932-943
[DOI] 10.2337/db20-0937.
[PMID] 33419759.
2021
How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?
Diabetes.
70(5):1021-1028
[DOI] 10.2337/dbi20-0045.
[PMID] 33632743.
2021
Image-Based Machine Learning Algorithms for Disease Characterization in the Human Type 1 Diabetes Pancreas.
The American journal of pathology.
191(3):454-462
[DOI] 10.1016/j.ajpath.2020.11.010.
[PMID] 33307036.
2021
Integrative analyses of TEDDY Omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes.
Genome biology.
22(1)
[DOI] 10.1186/s13059-021-02262-w.
[PMID] 33478573.
2021
Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report
Diabetes.
70(5):1123-1129
[DOI] 10.2337/db20-1103.
[PMID] 33632742.
2020
Addressing health disparities in type 1 diabetes through peer mentorship.
Pediatric diabetes.
21(1):120-127
[DOI] 10.1111/pedi.12935.
[PMID] 31617648.
2020
Combination Treatment with Antigen-Specific Dual-Sized Microparticle System Plus Anti-CD3 Immunotherapy Fails to Synergize to Improve Late-Stage Type 1 Diabetes Prevention in Nonobese Diabetic Mice.
ACS biomaterials science & engineering.
6(10):5941-5958
[DOI] 10.1021/acsbiomaterials.0c01075.
[PMID] 33320581.
2020
Commercially Available Insulin Products Demonstrate Stability Throughout the Cold Supply Chain Across the U.S.
Diabetes Care.
43(6):1360-1362
[DOI] 10.2337/dc19-1941.
[PMID] 32273273.
2020
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.
Diabetes technology & therapeutics.
22(12):948-953
[DOI] 10.1089/dia.2020.0305.
[PMID] 32833543.
2020
Exocrine Pancreas Dysfunction in Type 1 Diabetes.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
26(12):1505-1513
[DOI] 10.4158/EP-2020-0295.
[PMID] 33471743.
2020
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
The New England journal of medicine.
383(21):2007-2017
[DOI] 10.1056/NEJMoa2006136.
[PMID] 33207093.
2020
Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood.
Frontiers in immunology.
11
[DOI] 10.3389/fimmu.2020.00611.
[PMID] 32351504.
2020
Innate inflammation drives NK cell activation to impair Treg activity
Journal of Autoimmunity.
108
[DOI] 10.1016/j.jaut.2020.102417.
[PMID] 32035746.
2020
Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis
Diabetes.
69(3):413-423
[DOI] 10.2337/db19-0942.
[PMID] 31826866.
2020
Primary Care Providers in California and Florida Report Low Confidence in Providing Type 1 Diabetes Care
Clinical Diabetes.
38(2):159-165
[DOI] 10.2337/cd19-0060.
[PMID] 32327888.
2020
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
Diabetes.
69(8):1827-1832
[DOI] 10.2337/db20-0166.
[PMID] 32439823.
2020
Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers Through Undergraduate Research Curriculum
Medical Science Educator.
30(1):69-73
[DOI] 10.1007/s40670-019-00877-0.
[PMID] 34457640.
2020
Temporal Analysis of Amylase Expression in Control, Autoantibody-Positive, and Type 1 Diabetes Pancreatic Tissues
Diabetes.
69(1):60-66
[DOI] 10.2337/db19-0554.
[PMID] 31597639.
2020
The Neighborhood Deprivation Index and Provider Geocoding Identify Critical Catchment Areas for Diabetes Outreach.
The Journal of clinical endocrinology and metabolism.
105(9):3069-75
[DOI] 10.1210/clinem/dgaa462.
[PMID] 32676640.
2020
Use of Ecological Momentary Assessment to Measure Self-Monitoring of Blood Glucose Adherence in Youth With Type 1 Diabetes
Diabetes Spectrum.
33(3):280-289
[DOI] 10.2337/ds19-0041.
[PMID] 32848350.
2019
Advances in Type 1 Diabetes Technology Over the Last Decade.
European endocrinology.
15(2):70-76
[DOI] 10.17925/EE.2019.15.2.70.
[PMID] 31616496.
2019
Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk
Jama-Journal of the American Medical Association.
322(6):514-523
[DOI] 10.1001/jama.2019.10329.
[PMID] 31408136.
2019
Designing Online and Mobile Diabetes Education for Fathers of Children With Type 1 Diabetes: Mixed Methods Study
JMIR Diabetes.
4(3)
[DOI] 10.2196/13724.
[PMID] 31389338.
2019
Early Probiotic Supplementation and the Risk of Celiac Disease in Children at Genetic Risk
Nutrients.
11(8)
[DOI] 10.3390/nu11081790.
[PMID] 31382440.
2019
Human Factors Associated with Continuous Glucose Monitor Use in Patients with Diabetes: A Systematic Review.
Diabetes technology & therapeutics.
21(10):589-601
[DOI] 10.1089/dia.2019.0136.
[PMID] 31335196.
2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
Diabetes.
68(6):1267-1276
[DOI] 10.2337/db19-0057.
[PMID] 30967424.
2019
Metabolite-related dietary patterns and the development of islet autoimmunity
Scientific Reports.
9(1)
[DOI] 10.1038/s41598-019-51251-4.
[PMID] 31616039.
2019
Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy.
Journal of pediatric psychology.
44(1):21-31
[DOI] 10.1093/jpepsy/jsy064.
[PMID] 30184209.
2019
Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children.
Pediatric diabetes.
20(3):263-270
[DOI] 10.1111/pedi.12812.
[PMID] 30628751.
2019
Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes
Diabetes Care.
42(2):281-287
[DOI] 10.2337/dc18-1512.
[PMID] 30552130.
2019
The association between stressful life events and respiratory infections during the first 4 years of life: The Environmental Determinants of Diabetes in the Young study
Stress and Health.
35(3):289-303
[DOI] 10.1002/smi.2861.
[PMID] 30768831.
2018
Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.
Current diabetes reports.
18(10)
[DOI] 10.1007/s11892-018-1066-5.
[PMID] 30168021.
2018
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes
Diabetes Care.
41(9):1917-1925
[DOI] 10.2337/dc18-0494.
[PMID] 30012675.
2018
Presymptomatic screening for autoimmune β-cell disorder: Baby steps toward prevention?
Pediatric diabetes.
19(1):11-13
[DOI] 10.1111/pedi.12620.
[PMID] 29368416.
2018
Transition Education for Young Adults With Type 1 Diabetes: Pilot Feasibility Study for a Group Telehealth Intervention
JMIR Diabetes.
3(4)
[DOI] 10.2196/10909.
[PMID] 30401674.
2018
Understanding Pre-Type 1 Diabetes: The Key to Prevention.
Frontiers in endocrinology.
9
[DOI] 10.3389/fendo.2018.00070.
[PMID] 29559955.
2017
Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.
Molecular therapy. Methods & clinical development.
4:178-191
[DOI] 10.1016/j.omtm.2016.12.003.
[PMID] 28345003.
2017
High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes.
Diabetes care.
40(9):e122-e123
[DOI] 10.2337/dc17-0996.
[PMID] 28679687.
2017
Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults.
Frontiers in immunology.
8
[DOI] 10.3389/fimmu.2017.00655.
[PMID] 28659913.
2017
More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
The New England journal of medicine.
377(4)
[DOI] 10.1056/NEJMc1703468.
[PMID] 28748691.
2017
Poor Adherence to Ketone Testing in Patients With Type 1 Diabetes.
Diabetes care.
40(4):e38-e39
[DOI] 10.2337/dc16-2620.
[PMID] 28100607.
2017
Premeal insulin decreases arterial stiffness in children with type 1 diabetes.
Pediatric diabetes.
18(4):311-314
[DOI] 10.1111/pedi.12389.
[PMID] 27174580.
2017
T Cell Receptor Profiling in Type 1 Diabetes.
Current diabetes reports.
17(11)
[DOI] 10.1007/s11892-017-0946-4.
[PMID] 29022222.
2016
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Diabetes.
65(12):3765-3775
[PMID] 27669730.
2016
Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.
Clinical and experimental immunology.
183(3):350-7
[DOI] 10.1111/cei.12731.
[PMID] 26462724.
2016
The DIPP project: 20 years of discovery in type 1 diabetes.
Pediatric diabetes.
17 Suppl 22:5-7
[DOI] 10.1111/pedi.12398.
[PMID] 27411430.
2016
The influence of type 1 diabetes on pancreatic weight.
Diabetologia.
59(1):217-221
[DOI] 10.1007/s00125-015-3752-z.
[PMID] 26358584.
2016
Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry.
Pediatric diabetes.
17(1):15-20
[DOI] 10.1111/pedi.12231.
[PMID] 25330905.
2016
Treatable Diabetic Retinopathy Is Extremely Rare Among Pediatric T1D Exchange Clinic Registry Participants.
Diabetes care.
39(12):e218-e219
[PMID] 27852686.
2015
Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes.
Diabetes.
64(11):3885-90
[DOI] 10.2337/db15-0449.
[PMID] 26216853.
2015
Can we prevent type 1 diabetes?
Current diabetes reports.
15(11)
[DOI] 10.1007/s11892-015-0658-6.
[PMID] 26370697.
2015
Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.
Diabetes.
64(11):3873-84
[DOI] 10.2337/db15-0164.
[PMID] 26185279.
2015
Screening for T1D risk to reduce DKA is not economically viable.
Pediatric diabetes.
16(8):565-72
[DOI] 10.1111/pedi.12313.
[PMID] 26392298.
2014
A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience.
Pediatric diabetes.
15(2):110-7
[DOI] 10.1111/pedi.12067.
[PMID] 23957219.
2014
Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease.
The American journal of case reports.
15:212-5
[DOI] 10.12659/AJCR.890366.
[PMID] 24847412.
2013
Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
19(7):1126-9
[DOI] 10.1016/j.bbmt.2013.04.011.
[PMID] 23611977.
2013
The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFNγ production by PBMC.
Journal of autoimmunity.
44:8-12
[DOI] 10.1016/j.jaut.2013.06.001.
[PMID] 23891168.
2012
Characteristics of thawed autologous umbilical cord blood.
Transfusion.
52(10):2234-42
[DOI] 10.1111/j.1537-2995.2011.03556.x.
[PMID] 22321210.
2012
Neonatal diabetes mellitus and congenital diaphragmatic hernia: coincidence or concurrent etiology?
International journal of pediatric endocrinology.
2012(1)
[DOI] 10.1186/1687-9856-2012-21.
[PMID] 22781086.
2012
Tanner stage 4 breast development in adults: forensic implications.
Pediatrics.
130(4):e978-81
[DOI] 10.1542/peds.2011-3122.
[PMID] 22945406.
2012
Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research.
Current problems in pediatric and adolescent health care.
42(10):269-91
[DOI] 10.1016/j.cppeds.2012.07.002.
[PMID] 23046732.
2011
Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.
Diabetes care.
34(12):2567-9
[DOI] 10.2337/dc11-1406.
[PMID] 22011412.
2011
Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes.
Diabetes.
60(10):2566-70
[DOI] 10.2337/db11-0576.
[PMID] 21844098.
2010
Arterial stiffness, lipoprotein particle size, and lipoprotein particle concentration in children with type 1 diabetes.
Journal of pediatric endocrinology & metabolism : JPEM.
23(7):661-7
[PMID] 20857838.
2010
Efforts to prevent and halt autoimmune beta cell destruction.
Endocrinology and metabolism clinics of North America.
39(3):527-39
[DOI] 10.1016/j.ecl.2010.05.006.
[PMID] 20723818.
2010
Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
Journal of diabetes and its complications.
24(3):163-7
[DOI] 10.1016/j.jdiacomp.2008.12.004.
[PMID] 19217320.
2010
Type I diabetes. Preface.
Endocrinology and metabolism clinics of North America.
39(3):xvii-xviii
[DOI] 10.1016/j.ecl.2010.05.012.
[PMID] 20723814.
2009
Atorvastatin Differentially Affects Serum and Leukocyte Mcp-1 Concentrations With No Contribution From Nos3 Gene Variation.
Clinical Pharmacology & Therapeutics.
85:S74-S75
2009
Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.
Diabetes care.
32(11):2041-6
[DOI] 10.2337/dc09-0967.
[PMID] 19875605.
2009
Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
Diabetes.
58(10):2277-84
[DOI] 10.2337/db09-0557.
[PMID] 19628781.
2009
Pediatric Atorvastatin in Diabetes Trial (Padit): a Pilot Study To Determine the Effect of Atorvastatin On Arterial Stiffness and Endothelial Function in Children With Type 1 Diabetes Mellitus
Journal of Pediatric Endocrinology & Metabolism.
22:65-68
2009
Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus.
Journal of pediatric endocrinology & metabolism : JPEM.
22(1):65-8
[PMID] 19344076.
2009
Seroconversion in the Dpt-1 Study: Evidence of Triggering of Autoimmune Process At Different Ages
.
52
2009
Serum monocyte chemoattractant protein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes.
Diabetes care.
32(3):465-7
[DOI] 10.2337/dc08-1849.
[PMID] 19092169.
2009
The road not taken: a path to curing type 1 diabetes?
European journal of immunology.
39(8):2054-8
[DOI] 10.1002/eji.200939517.
[PMID] 19672902.
2009
Vascular dysfunction in glycogen storage disease type I.
The Journal of pediatrics.
154(4):588-91
[DOI] 10.1016/j.jpeds.2008.10.048.
[PMID] 19101686.
2009
Vitamin D levels in subjects with and without type 1 diabetes residing in a solar rich environment.
Diabetes care.
32(11):1977-9
[DOI] 10.2337/dc09-1089.
[PMID] 19675194.
2008
Autologous umbilical cord blood infusion for type 1 diabetes.
Experimental hematology.
36(6):710-5
[DOI] 10.1016/j.exphem.2008.01.009.
[PMID] 18358588.
2008
Characteristics and Cell Compostion of Privately Banked Autologous Umbilical Cord Blood (Ucb) Units Utilized for Autologous Ucb Infusion in Children With Type I Diabetes
Biology of Blood and Marrow Transplantation.
14(2)
[DOI] 10.1016/j.bbmt.2007.12.126.
2008
Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency.
Annals of the New York Academy of Sciences.
1150:152-6
[DOI] 10.1196/annals.1447.049.
[PMID] 19120286.
2007
Adverse impact of temperature and humidity on blood glucose monitoring reliability: a pilot study.
Diabetes technology & therapeutics.
9(1):1-9
[PMID] 17316092.
2007
Assessing the in vitro suppressive capacity of regulatory T cells.
Immunological investigations.
36(5-6):607-28
[PMID] 18161521.
2007
Congenital craniopharyngioma and hypercalcemia induced by parathyroid hormone-related protein.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
13(1):67-71
[PMID] 17360305.
2007
Endocrine complications of childhood cancer therapy: evaluation and management.
Pediatric endocrinology reviews : PER.
4(3):196-204
[PMID] 17551480.
2007
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
Diabetes.
56(3):604-12
[PMID] 17327427.
2007
NOS3 polymorphisms are associated with arterial stiffness in children with type 1 diabetes.
Diabetes care.
30(3):689-93
[PMID] 17327342.
2007
Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes.
Pediatric diabetes.
8(4):193-8
[PMID] 17659060.
2007
Type 1 diabetes intervention trials 2007: where are we and where are we going?
Current opinion in endocrinology, diabetes, and obesity.
14(4):283-7
[PMID] 17940453.
2006
Arterial thrombosis resulting in amputation in a child with poorly controlled type 1 diabetes and heterozygous Factor V Leiden mutation.
Pediatric diabetes.
7(4):229-31
[PMID] 16911011.
2006
Serum superoxide dismutase activity and nitric oxide do not correlate with arterial stiffness in children with type 1 diabetes mellitus.
Journal of pediatric endocrinology & metabolism : JPEM.
19(3):267-9
[PMID] 16607928.
2005
Type 1 diabetes mellitus: etiology, presentation, and management.
Pediatric clinics of North America.
52(6):1553-78
[PMID] 16301083.
2004
Blood lymphocyte chimerism associated with IVF and monochorionic dizygous twinning: case report.
Human reproduction (Oxford, England).
19(12):2816-21
[PMID] 15375077.
2004
Predictors of control of diabetes: monitoring may be the key.
The Journal of pediatrics.
144(5):660-1
[PMID] 15127007.
Grants
Apr 2024
ACTIVE
A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40Lantagonist monoclonal antibody, for preservation of pancreatic ?-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy
Role: Principal Investigator
Funding: SANOFI
Apr 2024
ACTIVE
The T1D Financial Toolkit for Emerging Adults
Role: Principal Investigator
Funding: UNIVERSITY HOSPITALS CLEVELAND MED CTR
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Dec 2023
ACTIVE
Implementation of Early Stage T1D Education and Support (ESTES)
Role: Principal Investigator
Funding: UNIV OF COLORADO
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Aug 2023
ACTIVE
Understanding T1D and Insulin-Requiring Diabetes in Federally Qualified Health Centers (FQHC): A National Needs Assessment
Role: Co-Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jul 2023
– Jun 2024
Project ECHO Teleclinics for Rural Providers
Role: Co-Investigator
Funding: FL DEPT OF HLTH
Jul 2023
– Jun 2024
TrialNet Clinic Agreement – Site #0001
Role: Principal Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Jun 2023
ACTIVE
Immune Function and the Progression to Type 1 Diabetes
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Apr 2023
ACTIVE
The TEDDY Data Coordinating Center
Role: Principal Investigator
Funding: AUGUSTA UNIVERSITY
via NATL INST OF HLTH NIDDK
Jan 2023
– Jun 2023
UFDI ECHO DIABETES PROPOSAL
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Jan 2023
ACTIVE
Natural History and Mechanisms of Exocrine Pancreatic Dysfunction in Pre-Type 1 Diabetes
Role: Other
Funding: NATL INST OF HLTH NIDDK
Jan 2023
– Jun 2024
Georgia Center for Diabetes Translation Research Renewal – PILOT
Role: Other
Funding: GEORGIA CTR FOR DIABETES TRANSLATION RES
via NATL INST OF HLTH NIDDK
Aug 2022
ACTIVE
Connected Care Pilot Program
Role: Principal Investigator
Funding: US FED COMMUNICATIONS COM
Jul 2022
– Jun 2023
Natural History and Mechanisms of Exocrine Pancreatic Dysfunction in Pre-Type 1 Diabetes
Role: Other
Funding: PEDIATRIC ENDOCRINE SOCIETY
Jul 2022
– Jun 2023
TrialNet affiliates reimbursement.
Role: Principal Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Dec 2021
ACTIVE
A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus
Role: Principal Investigator
Funding: PSI CRO
via PROVENTION BIO
Nov 2021
ACTIVE
INHALE 1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
via MANNKIND
Sep 2021
– Aug 2024
Natural History and Mechanisms of Exocrine Pancreatic Dysfunction in Pre-Type 1 Diabetes
Role: Other
Funding: NATL INST OF HLTH NIDDK
Jul 2021
ACTIVE
Development of a Predictive Response Signature to Anti-Thymocyte Globulin in Type 1 Diabetes
Role: Other
Funding: NATL INST OF HLTH NIDDK
Jul 2021
ACTIVE
A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin in Pediatric Subjects wi
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
via MANNKIND
Jul 2021
– Jun 2022
Natural History and Mechanisms of Exocrine Pancreatic Dysfunction in Pre-Type 1 Diabetes
Role: Other
Funding: PEDIATRIC ENDOCRINE SOCIETY
Jul 2021
– Jun 2022
TrialNet Affiliate Services reimbursement
Role: Principal Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
May 2021
ACTIVE
Generation of Islet Specific T Follicular Regulatory Like Cells for Autologous Cell Therapy of Type 1 Diabetes
Role: Other
Funding: NATL INST OF HLTH NIDDK
Mar 2021
ACTIVE
Increasing Access to Telemedicine Services Through County Extension Offices
Role: Principal Investigator
Funding: US DEPT OF AG RURAL DEVELOPMENT
Oct 2020
– Mar 2023
Data Coordinating Center for the Consortium for Identification of Environmental Determinants of Diabetes in the Young (TERRY) Study
Role: Principal Investigator
Funding: AUGUSTA UNIVERSITY
via NATL INST OF HLTH NIDDK
Sep 2020
ACTIVE
Pre-Regulatory Inspection Readiness Visit (PRV-031) for upcoming teplizumab BLA – University of FL
Role: Principal Investigator
Funding: PROVENTION BIO
Aug 2020
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Aug 2020
ACTIVE
Understanding pancreatic endocrine and exocrine loss in pre-type 1 diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2020
– Sep 2021
A Validation Study of Home Blood Collection for HbA1c Measurement
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
Jul 2020
– Jun 2021
6163-1082-11 TrialNet Affiliate Services
Role: Principal Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Apr 2020
– Mar 2021
Emergency Funding to Support Underserved T1D Populations Impacted by the COVID-19 Pandemic
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Mar 2020
– Dec 2020
COVID-19 Telemedicine: Department of Pediatrics
Role: Principal Investigator
Funding: US FED COMMUNICATIONS COM
Mar 2020
ACTIVE
An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes
Role: Principal Investigator
Funding: PROVENTION BIO
Mar 2020
– Aug 2023
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Role: Principal Investigator
Funding: DEXCOM
Feb 2020
ACTIVE
TrialNet Clinical Center infrastructure support services
Role: Principal Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Sep 2019
– Sep 2024
A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D)
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via PROVENTION BIO
Sep 2019
ACTIVE
Evaluation of the safety, tolerability and general response to Lactobacillus johnsonii N6.2 in children and adolescents with T1D
Role: Co-Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Sep 2019
ACTIVE
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2019
– Jun 2024
Project ECHO T1D: HCT Trial
Role: Principal Investigator
Funding: STANFORD UNIV
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Apr 2019
– Sep 2020
Data Coordinating Center for the Consortium for Identification of Environmental Determinants of Diabetes in the Young (TEDDY) Study
Role: Principal Investigator
Funding: AUGUSTA UNIVERSITY
via NATL INST OF HLTH NIDDK
Oct 2018
– Sep 2022
T cell receptor sequencing in type 1 diabetes – biomarker discovery and technology development
Role: Co-Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Aug 2018
– Jul 2020
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A proof of Concept Study.
Role: Principal Investigator
Funding: DIABETES ACTION RESEARCH AND EDU FOU
Jun 2018
– May 2023
Immune Function and the Progression to Type 1 Diabetes
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jun 2018
– Jun 2019
Characterization of T cell Autoreactivity in Type 1 Diabetes
Role: Faculty
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Apr 2018
– Mar 2019
Data Coordinating Center (TEDDY)
Role: Principal Investigator
Funding: AUGUSTA UNIVERSITY
via NATL INST OF HLTH NIDDK
Mar 2018
– Apr 2019
Pediatric Endocrine Society Travel Award
Role: Other
Funding: PEDIATRIC ENDOCRINE SOCIETY
via ELI LILLY AND CO
Mar 2018
– May 2021
214 Operating Account
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jan 2018
– Sep 2021
Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA? in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via MANNKIND
Jan 2018
– Jan 2022
Hybrid Closed Loop Insulin Delivery System Data Collection (HYCLO)
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jan 2018
– Jun 2019
ECHO Type 1 Diabetes: A Feasibility and Planning Proposal
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jan 2018
– Mar 2018
Data Coordinating Center for the Consortium for Identification of Environmental Determinants of Diabetes in the Young (TEDDY) Study
Role: Principal Investigator
Funding: AUGUSTA UNIVERSITY
via NATL INST OF HLTH NIDDK
Dec 2017
– Nov 2022
McJunkin Family Foundation Diabetes
Role: Principal Investigator
Funding: UF FOUNDATION
via MCJUNKIN FAMILY FOUNDATION
Sep 2017
– Nov 2018
Young Adult Racial Disparities in Type 1 Diabetes (YARDD)
Role: Other
Funding: JAEB CTR FOR HLTH RES
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Sep 2017
– Oct 2018
Type 1 Diabetes EXercise Initiative (T1-Dexi) Steering Committee
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Aug 2017
– Jul 2018
Low-Dose IL-2 in Established T1D
Role: Co-Investigator
Funding: UNIV OF MIAMI
via NATL INST OF HLTH NIAID
Jul 2017
– Jun 2018
TrialNet Affiliate Services FY 17-18
Role: Project Manager
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Jul 2017
– May 2018
PES Travel Grant
Role: Other
Funding: PEDIATRIC ENDOCRINE SOCIETY
via ELI LILLY AND CO
Jun 2017
– Dec 2017
Pediatric Endocrine Society Travel Award
Role: Other
Funding: PEDIATRIC ENDOCRINE SOCIETY
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2017
– Feb 2018
Estimating the Lifetime Costs of Type 1 Diabetes
Role: Principal Investigator
Funding: BOSTON HEALTH ECONOMICS INC
Jan 2017
– Jul 2018
A Phase 3B Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients with Type 1 Diabetes
Role: Principal Investigator
Funding: EMMES
via XERIS PHARMACEUTICALS INC
Dec 2016
– Aug 2021
SIMPONI to Arrest B-Cell loss in Type 1 Diabetes- T1GER
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Sep 2016
– Sep 2021
A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal CD4+CD25+CD127lo/-FOXP3+ Regulatory T-cells [Tregs]) in Adolescents with Recent Onset Type 1 Diabetes Mellitus (T1DM)
Role: Principal Investigator
Funding: CALADRIUS BIOSCIENCES
Jul 2016
– Jun 2023
FLDOH CMS Disease Management Contract – COQWY
Role: Project Manager
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
Jul 2016
– Jan 2020
Strategies to Encourage CGM use in Young Children (SENCE)
Role: Co-Investigator
Funding: INDIANA UNIV
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jul 2016
– Jun 2017
TrialNet Affiliate Services
Role: Co-Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH
Jun 2016
– Nov 2019
Clinical Trial Planning Grant for Treg Therapy in Type I Diabetes
Role: Principal Investigator
Funding: CORD BLOOD REGISTRY
Jun 2016
– Dec 2017
Data Coordinating Center
Role: Principal Investigator
Funding: AUGUSTA UNIVERSITY
via NATL INST OF HLTH NIDDK
Aug 2015
– Apr 2016
OPEN-LABEL, SINGLE-ARM, MULTIPLE-DOSE SAFETY, TITRATION, AND, PHARMACOKINETIC TRIAL OF AFREZZA? IN PEDIATRIC PATIENTS AGES,
Role: Principal Investigator
Funding: SANOFI US SERVICES
Aug 2015
– Jul 2017
Reversing Type 1 Diabetes after it is Established: Follow up, Phase II
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jul 2015
– Jun 2016
Trialnet affiliate services
Role: Project Manager
Funding: UNIV OF SOUTH FLORIDA
Jan 2015
– Jul 2016
Cord Blood Expansion of Regulatory T cells
Role: Project Manager
Funding: CBR SYSTEMS
Jan 2015
– Dec 2016
Acute effect of a mixed meal with and without insulin on arterial stiffness, a prospective randomized study
Role: Principal Investigator
Funding: DIABETES ACTION RESEARCH AND EDU FOU
Jan 2015
– Oct 2016
Dissociation of Obesity and insulin sensitivity in 2 rare short stature syndromes
Role: Principal Investigator
Funding: GENENTECH INC
Nov 2014
– Dec 2018
Phase II Clinical Trial in New Onset Type 1 Diabetes Patients
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Nov 2014
– May 2018
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin?) and Pegylated GCSF (Neulasta?) in New Onset Type 1 Diabetes Protocol TN-19
Role: Principal Investigator
Funding: SANOFI US SERVICES
Sep 2014
– May 2016
Data Coordinating Center
Role: Principal Investigator
Funding: *GEORGIA REGENTS UNIVERSITY
via NATL INST OF HLTH NIDDK
Jun 2014
– Apr 2020
TrialNet: University of Florida Clinical Center and Network
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Nov 2013
– Oct 2016
T1D Exchange Biobank
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
Sep 2013
– Aug 2017
Pancreatic Volume in Preclinical Type 1 Diabetes
Role: Project Manager
Funding: NATL INST OF HLTH NIDDK
Apr 2012
– Mar 2016
T1D Exchange: BRI Biobank Operations Center
Role: Principal Investigator
Funding: BENAROYA RES INST AT VA MASON
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Feb 2012
– Mar 2019
T1d exchange type 1 diabetes network ancilliary study: residual c-peptide in patients with type 1 diabetes
Role: Principal Investigator
Funding: JAEB CTR FOR HLTH RES
Jul 2007
– Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Education
Masters Clinical Investigation
2006
·
University of Florida
Medical Degree
2000
·
University of Florida
BS (Biology and Chemistry)
1996
·
Duke University
Contact Details
Phones:
- Business:
- (352) 273-9264
Emails:
- Business:
- hallerms@ufl.edu
Addresses:
- Business Mailing:
-
PO BOX 100296
MICHAEL HALLER, MD
GAINESVILLE FL 326100296 - Business Street:
-
1600 SW ARCHER RD J591
GAINESVILLE FL 32610